| Literature DB >> 30165427 |
Thushara Perera1,2, Joy L Tan1,2, Michael H Cole3, Shivy A C Yohanandan1, Paul Silberstein4, Raymond Cook4, Richard Peppard1,5, Tipu Aziz6, Terry Coyne7, Peter Brown6,8, Peter A Silburn7, Wesley Thevathasan1,9,10.
Abstract
Impaired balance is a major contributor to falls and diminished quality of life in Parkinson's disease, yet the pathophysiology is poorly understood. Here, we assessed if patients with Parkinson's disease and severe clinical balance impairment have deficits in the intermittent and continuous control systems proposed to maintain upright stance, and furthermore, whether such deficits are potentially reversible, with the experimental therapy of pedunculopontine nucleus deep brain stimulation. Two subject groups were assessed: (i) 13 patients with Parkinson's disease and severe clinical balance impairment, implanted with pedunculopontine nucleus deep brain stimulators; and (ii) 13 healthy control subjects. Patients were assessed in the OFF medication state and blinded to two conditions; off and on pedunculopontine nucleus stimulation. Postural sway data (deviations in centre of pressure) were collected during quiet stance using posturography. Intermittent control of sway was assessed by calculating the frequency of intermittent switching behaviour (discontinuities), derived using a wavelet-based transformation of the sway time series. Continuous control of sway was assessed with a proportional-integral-derivative (PID) controller model using ballistic reaction time as a measure of feedback delay. Clinical balance impairment was assessed using the 'pull test' to rate postural reflexes and by rating attempts to arise from sitting to standing. Patients with Parkinson's disease demonstrated reduced intermittent switching of postural sway compared with healthy controls. Patients also had abnormal feedback gains in postural sway according to the PID model. Pedunculopontine nucleus stimulation improved intermittent switching of postural sway, feedback gains in the PID model and clinical balance impairment. Clinical balance impairment correlated with intermittent switching of postural sway (rho = - 0.705, P < 0.001) and feedback gains in the PID model (rho = 0.619, P = 0.011). These results suggest that dysfunctional intermittent and continuous control systems may contribute to the pathophysiology of clinical balance impairment in Parkinson's disease. Clinical balance impairment and their related control system deficits are potentially reversible, as demonstrated by their improvement with pedunculopontine nucleus deep brain stimulation.Entities:
Mesh:
Year: 2018 PMID: 30165427 PMCID: PMC6158752 DOI: 10.1093/brain/awy216
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Parkinson’s disease patients with balance impairment and PPN DBS
| Patient | Age/ gender | Centre | PD duration, years | MMSE | UK Brain Bank criteria | LED (postop) | UPDRS III off/on meds (postop) | IT27–30 off/on meds (postop) | PPN DBS duration, years, months | GFQ pre/ postop | FOG pre/ postop | Falls Q pre/ postop | Clinical balance impairment (off/on DBS) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 61 F | Brisbane | 10 | 30 | D,A,P | 800 | 40/23 | 10/9 | 2, 0 | 61/36 | 24/16 | 4/3 | 5/4 |
| 2 | 72 M | Brisbane | 18 | 30 | D,A,T,P | 2500 | 25/17 | 6/6 | 2, 6 | 30/16 | 14/11 | 4/2 | 3/3 |
| 3 | 76 M | Brisbane | 6 | 28 | A,P | 600 | 26/14 | 6/4 | 2, 0 | 51/18 | 22/7 | 3/3 | 2/1 |
| 4 | 72 F | Brisbane | 10 | 28 | A,T,P | 950 | 38/22 | 11/8 | 2, 0 | 48/26 | 22/13 | 4/2 | 5/3 |
| 5 | 71 M | Brisbane | 4 | 29 | D,T,P | 1550 | 27/18 | 5/5 | 0, 6 | 48/21 | 18/9 | 4/3 | 2/2 |
| 6 | 77 M | Brisbane | 6 | 30 | A,P | 1400 | 31/17 | 10/10 | 0, 6 | 31/14 | 16/6 | 1/2 | 5/5 |
| 7 | 56 M | Oxford | 20 | 30 | D,A,P | 850 | 51/19 | 8/6 | 1, 0 | 38/40 | 14/15 | 4/4 | 3/2 |
| 8 | 78 F | Brisbane | 11 | 27 | A, T, P | 1450 | 26/10 | 13/5 | 0, 7 | 46/30 | 20/16 | 4/3 | ^/^ |
| 9 | 74 M | Brisbane | 9 | 30 | A,T,P | 1200 | 54/42 | 8/5 | 4, 6 | ^/37 | ^/15 | ^/3 | 4/3 |
| 10 | 75 M | Sydney | 12 | 26 | A,T,P | 1200 | 32/24 | 7/6 | 1, 4 | ^/26 | ^/14 | ^/1 | 4/3 |
| 11 | 72 M | Brisbane | 8 | 30 | D,A,P | 800 | 33/25 | 6/4 | 2, 7 | ^/20 | ^/8 | ^/2 | 3/1 |
| 12 | 62 M | Brisbane | 14 | 29 | D,A,T,P | 800 | 38/28 | 5/5 | 4, 5 | ^/32 | ^/11 | ^/3 | 2/2 |
| 13 | 64 M | Melbourne | 9 | 28 | D,A,T,P | 1000 | 44/26 | 6/4 | 5, 0 | ^/47 | ^/19 | ^/4 | 3/3 |
Postoperative (postop) clinical assessments were performed on the same day as experiments.
^ = not known; Clinical balance impairment (score/8) representing summation of UPDRS items of chair rise (item 27; score/4) and the pull test (item 30; score/4); FallsQ = Falls Question (score/4); FOGQ = Freezing of Gait Questionnaire (score/24); GFQ = Gait and Falls Questionnaire (score/64); IT27–30 = items 27–30 of UPDRS, assessing gait, posture and balance (score/16); MMSE = Mini Mental State Examination (score/30); UK Brain bank criteria: D = dyskinesias; A = asymmetry persistent; T = tremor at rest; P = progressive disease course; UPDRS III = part III (motor) of the Unified Parkinson’s Disease Rating Scale (score/108).
LED = l-DOPA equivalent dose, mg/day.
Figure 1Localization of stimulation locations (coloured dots) represented in Montreal Neurological Institute (MNI) space (sagittal and coronal views). The relative location/extent of the pedunculopontine nucleus has been outlined on the sagittal view, based on cholineacetyltransferase immunohistochemical (ChAT5) staining in the human. Coordinates were calculated in millimetres from midline (laterality), ventrodorsal distance (d) from floor of the fourth ventricle and rostro-caudal distance (h) from a pontomesencephalic line connecting the pontomesencephalic junction to the inferior colliculi caudal margin, as described previously (Ferraye ). The mean (ranges) of these stimulation site coordinates were as follows: laterality 6.481 mm (2.5 to 8.7 mm), ventrodorsal distance (d) 6.4 mm (4.1 to 9.2 mm), rostro-caudal distance (h) 6.1 mm (−2.2 to −12.5 mm). IC = inferior colliculus; PM = ponto-mesencephalic line connecting the pontomesencephalic junction to the caudal end of the inferior colliculi; SC = superior colliculus.
Figure 2Schematic showing the inverted pendulum model of human balance (A) used in the PID control system (B). The setpoint input of the PID controller is fixed at zero and acquired posturography time-series data (converted to angular displacement using participant’s height) gives the output allowing estimation of the factors K (proportional), K (integral) and K (derivative).
Figure 3Postural sway parameters (medians and interquartile ranges) for healthy controls and Parkinson’s disease patients (off and on PPN DBS). (A) Intermittent switching (abrupt, high amplitude redirections) of postural sway. (B) Sway C90 area (of an ellipse measured in millimetres squared that encompasses 90% of data points). (C) Sway velocity (mean of the differentiated time series). (D–F) PID continuous control model gains in time domains of past (D), present (E) and future (F) scaled in arbitrary units (AU). Differences between groups and conditions are indicated by bridges with P-values.
Figure 4Example postural sway traces of a healthy control subject and Parkinson’s disease Patient 5 (off and on PPN DBS) acquired during quiet stance on a force-plate (30-s trial). (A–C) Panels show movements in centre of pressure in two planes. Patients with Parkinson’s disease have increased sway area but this did not change with PPN DBS. (D–F) Root mean square (RMS) of sway in millimetres. (G–I) The results of the wavelet-based transformation of the RMS sway time series with intermittent switching behaviour (abrupt redirections) clearly evident as instances of high frequency arising from the baseline.
Figure 5Correlations between clinical balance impairment and control system metrics. Correlations between clinical balance impairment (score/8), which represents summation of UPDRS items of chair rise (item 27; score/4) and the pull test (item 30; score/4) with measures of intermittent and continuous control of sway, namely: (A) intermittent switching (more switching behaviour correlates with lower balance impairment); and (B) the difference in normalized PID values relative to healthy controls (lower PID model gains relative to controls correlates with lower balance impairment).